Healthcare Industry News: HSMN NewsFeed
News Release - January 24, 2020
Anat Hakim to join Lilly as General CounselINDIANAPOLIS, Jan. 24, 2020 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that Anat Hakim will join the company on February 3, 2020 as senior vice-president and general counsel. Hakim succeeds Michael J. Harrington who will retire on January 31, 2020.
"I am excited to welcome Anat to Lilly as our new general counsel," said David A. Ricks, Lilly's chairman and CEO. "Anat's legal expertise and prior experiences in the pharmaceutical industry, across healthcare more broadly, and as general counsel at WellCare Health Plans make her the ideal person to lead Lilly's law division. I look forward to the external perspective and informed legal opinion that she will bring to our executive team as we continue to progress our innovation-based strategy and develop new medicines for patients around the world."
Hakim most recently served as executive vice president, general counsel and secretary at WellCare Health Plans, where she provided strategic counsel on a broad range of legal, business and operational matters for the company and its board of directors. She was recently recognized as General Counsel of the Year in 2019 by Corporate Counsel. Before WellCare, Hakim served as divisional vice president, associate general counsel for intellectual property litigation at Abbott Laboratories, and later as the company's divisional vice president, associate general counsel for litigation. She began her career at Latham Watkins after earning her law degree from Harvard University, and also worked for 12 years at Foley & Lardner LLP.
"The legal team at Lilly is incredibly talented and is trusted to provide expert counsel to all aspects of the company's operations," Hakim said. "I'm thrilled to lead the law division and to be joining Lilly at such an exciting time for the company. Lilly's focus on innovation, its promising pipeline of new medicines, and its desire to make medicines more affordable for patients make it the ideal place for me. I can't wait to get started."
Ricks also commented, "I want to take this opportunity to again thank Mike Harrington for his significant contributions throughout his time at Lilly. Over the past eight years, Mike has very successfully led our legal organization and was a great partner to me and the Lilly Board of Directors. We are grateful for his leadership and wish him well in this next chapter of his life."
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com. C-LLY
This press release contains forward-looking statements about leadership changes and reflects Lilly's current beliefs. There are risks and uncertainties related to leadership changes. For discussion of important risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
Source: Eli Lilly
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsEmgality(R) Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine and a History of Preventive Treatment Failure
Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines
Lilly's Taltz(R) (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis